Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG Somatropin in Children With Idiopathic Short Stature
NCT03221088Phase 2Unknown
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Jun 2015
- Primary completion
- Dec 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of peg-somatropin in Idiopathic Short Stature (ISS) (3 arms), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoint: Change in Height Standard Deviation Score for Chronological Age at 52 weeks. Status: unknown.
02
Drugs
peg-somatropin
03
Conditions
Idiopathic Short Stature (ISS)
Beyond the preview
Go deeper on NCT03221088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03221088.